Neuronetics is trading 6.37% down at $2.72, mainly amid global risk-off conditions, with the 10-year Treasury yield reaching 5.02%, elevated oil prices, and pressure on growth-sensitive equities ahead of the Federal Reserve decision.

  • Shares fell from the September 14 close of $2.90.
  • No new company-specific negative announcement, earnings release, regulatory action, or analyst downgrade was identified for September 15, 2026.
  • The recent B. Riley Buy initiation was dated September 11, not September 15.